These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9675729)

  • 1. New therapeutic products and difficult decisions. The case of recombinant factor VIII in the management of haemophilia A.
    Green C; Akehurst R
    J Public Health Med; 1998 Jun; 20(2):137-8. PubMed ID: 9675729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
    Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Who should receive recombinant factor VIII?
    Giangrande PL
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S25-7. PubMed ID: 9351533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new albumin-free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement?
    Josephson CD; Abshire T
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):441-6. PubMed ID: 16163220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The uptake of recombinant Factor VIII in the Netherlands.
    Zwart-van Rijkom JE; Plug I; Rosendaal FR; Leufkens HG; Broekmans AW;
    Br J Haematol; 2002 Nov; 119(2):332-41. PubMed ID: 12406065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    Haemophilia; 2017 May; 23(3):408-416. PubMed ID: 28233383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
    Epstein J; Xiong Y; Woo P; Li-McLeod J; Spotts G
    Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
    Singleton E; Smith J; Kavanagh M; Nolan B; White B
    Thromb Haemost; 2007 Dec; 98(6):1188-92. PubMed ID: 18064312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
    Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
    Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant clotting factors in the treatment of hemophilia.
    Lee C
    Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.
    Musso R
    Drugs Today (Barc); 2008 Oct; 44(10):735-50. PubMed ID: 19137127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia A.
    Mannucci PM; Cortesi PA; Di Minno MND; Sanò M; Mantovani LG; Di Minno G
    Haemophilia; 2021 Jul; 27(4):e422-e433. PubMed ID: 33955638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baby hamster kidney cell-derived recombinant factor VIII: a quarter century of learning and clinical experience.
    Afonja O; Kozak R; Petraro P; Michaels LA; Mathew P; Lemm G; Kessler C
    Expert Rev Hematol; 2016 Dec; 9(12):1151-1164. PubMed ID: 27841041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 2003.
    Blatny J; Komrska V; Blazek B; Penka M; Ovesna P;
    Blood Coagul Fibrinolysis; 2015 Sep; 26(6):673-8. PubMed ID: 25886834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Million dollar miracles.
    Smith SD
    Minn Med; 2006 Apr; 89(4):30-5, 51. PubMed ID: 16681280
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness analysis of alternative factor VIII products in treatment of haemophilia A.
    Hay JW; Ernst RL; Kessler CM
    Haemophilia; 1999 May; 5(3):191-202. PubMed ID: 10444287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.
    Hermans C; Mahlangu J; Booth J; Schütz H; Santagostino E; Young G; Lee HY; Steinitz-Trost KN; Blanchette V; Berntorp E
    Haemophilia; 2018 May; 24(3):376-384. PubMed ID: 29732708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.